Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Glenmark inks pact with Lubrizol arm Particle Sciences to develop generic cancer drug

As per the deal, Glenmark will have global exclusive marketing rights of the product - a generic version of cancer drug Abraxane that had worldwide sales of $ 967 million in 2015

Rakesh Rao  |  Mumbai 

Glenmark Pharmaceuticals has formed a strategic alliance with the US-based Particle Sciences Inc, a Lubrizol company, for development and marketing of generic version of Abraxane, a cancer drug. “The company has entered into a strategic development, license and commercialisation agreement with Particle Sciences Inc to develop and market a generic version of Celgene’s Abraxane product - paclitaxel protein (albumin)-bound particles for injectable suspension,” said Glenmark Pharmaceuticals in a press release. Abraxane, marketed globally by Celgene, has ...

TO READ THE FULL STORY, SUBSCRIBE NOW AT JUST Rs 149 A MONTH

Key stories on business-standard.com are available to premium subscribers only.

LOGIN

EMAIL / USER NAME
PASSWORD
REMEMBER ME Forgot password?

Not a member yet ? Resister Now

Connect using any below

  • Don't lose the opportunity of saving $26.77 per month
  • Don't lose the opportunity of saving $26.77 per month
Total Amount
Rs. 0.00
To proceed, kindly select a subscription package

WHAT YOU GET

On Business Standard Digital

  • Access your subscription from anywhere. Be it your computer, tablet or smartphone using a browser or the App, Your Choice.
  • Access to exclusive content, features, opinions and comment, hand-picked by our editors, just for you.
  • Pick your 5 favourite companies. Get all the news upates at the end of each day through E-Mail.
  • Pick the industry that you want to track. And get a daily news letter specific to that industry. Cut out the clutter.
  • And stay on top of your investments. Track stock prices in your portfolio
  • Access 18 years of archival data

On Digital

  • Seamless access to WSJ.com with your Business Standard digital account.
  • Experience the best of the Journal's reporting, video and interactive features.
  • Read about the people and events shaping business, finance, technology, politics, technology and culture.
  • Stay informed with newsletters - an easy way to get WSJ content straight to your inbox - making life easier on your busiest days.
  • More business executives read the Journal globally than any other publication.
*Note :
Our Partners are proud to be associated with this initiative and will contribute Rs 100 x 6 months thereafter, standard rate of Rs 149 will be charged.
Offer valid for Indian residents only
Requires you to share personal information like PAN, Date of Birth, and Income.
*Annual saving on WSJ subscription price of US$ 347.88 (12 months @ US$ 28.99 per month)
* 1US$ = 67.50 INR.
*Please note that this offer is not valid if you are/were a registered/existing user on WSJ Digital
First Published: Mon, September 19 2016. 17:19 IST
RECOMMENDED FOR YOU

Glenmark inks pact with Lubrizol arm Particle Sciences to develop generic cancer drug

As per the deal, Glenmark will have global exclusive marketing rights of the product - a generic version of cancer drug Abraxane that had worldwide sales of $ 967 million in 2015

As per the deal, Glenmark will have global exclusive marketing rights of the product - a generic version of cancer drug Abraxane that had worldwide sales of $ 967 million in 2015 Glenmark Pharmaceuticals has formed a strategic alliance with the US-based Particle Sciences Inc, a Lubrizol company, for development and marketing of generic version of Abraxane, a cancer drug. “The company has entered into a strategic development, license and commercialisation agreement with Particle Sciences Inc to develop and market a generic version of Celgene’s Abraxane product - paclitaxel protein (albumin)-bound particles for injectable suspension,” said Glenmark Pharmaceuticals in a press release. Abraxane, marketed globally by Celgene, has ... image
Business Standard
177 22

Glenmark inks pact with Lubrizol arm Particle Sciences to develop generic cancer drug

As per the deal, Glenmark will have global exclusive marketing rights of the product - a generic version of cancer drug Abraxane that had worldwide sales of $ 967 million in 2015

Glenmark Pharmaceuticals has formed a strategic alliance with the US-based Particle Sciences Inc, a Lubrizol company, for development and marketing of generic version of Abraxane, a cancer drug. “The company has entered into a strategic development, license and commercialisation agreement with Particle Sciences Inc to develop and market a generic version of Celgene’s Abraxane product - paclitaxel protein (albumin)-bound particles for injectable suspension,” said Glenmark Pharmaceuticals in a press release. Abraxane, marketed globally by Celgene, has ...

image
Business Standard
177 22